Literature DB >> 32267931

Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.

Nabila Belhouachi1, Aliki Xochelli2, Myriam Boudjoghra1, Claude Lesty1, Nathalie Cassoux3, Christine Fardeau4, Thi Ha Chau Tran5, Sylvain Choquet6, Bishnu Sarker7, Caroline Houillier8, Agusti Alentorn8, Phuc LeHoang4, Carole Soussain9, Valerie Touitou4, Helene Merle-Beral1, Khe Hoang-Xuan8, Bahram Bodaghi4, Kostas Stamatopoulos2, Frederic Davi1.   

Abstract

Primary vitreoretinal lymphoma (PVRL) is a high-grade lymphoma affecting the vitreous and/or the retina. The vast majority of cases are histopathologically classified as diffuse large B-cell lymphoma (DLBCL) and considered a subtype of primary central nervous system lymphoma (PCNSL). To obtain more insight into the ontogenetic relationship between PVRL and PCNSL, we adopted an immunogenetic perspective and explored the respective immunoglobulin gene repertoire profiles from 55 PVRL cases and 48 PCNSL cases. In addition, considering that both entities are predominantly related to activated B-cell (ABC) DLBCL, we compared their repertoire with that of publicly available 262 immunoglobulin heavy variable domain gene rearrangement sequences from systemic ABC-type DLBCLs. PVRL displayed a strikingly biased repertoire, with the IGHV4-34 gene being used in 63.6% of cases, which was significantly higher than in PCNSL (34.7%) or in DLBCL (30.2%). Further repertoire bias was evident by (1) restricted associations of IGHV4-34 expressing heavy chains, with κ light chains utilizing the IGKV3-20/IGKJ1 gene pair, including 5 cases with quasi-identical sequences, and (2) the presence of a subset of stereotyped IGHV3-7 rearrangements. All PVRL IGHV sequences were highly mutated, with evidence of antigen selection and ongoing mutations. Finally, half of PVRL and PCNSL cases carried the MYD88 L265P mutation, which was present in all 4 PVRL cases with stereotyped IGHV3-7 rearrangements. In conclusion, the massive bias in the immunoglobulin gene repertoire of PVRL delineates it from PCNSL and points to antigen selection as a major driving force in their development.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 32267931      PMCID: PMC7160258          DOI: 10.1182/bloodadvances.2019000980

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  80 in total

1.  Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.

Authors:  Manuel Montesinos-Rongen; Elzbieta Godlewska; Anna Brunn; Otmar D Wiestler; Reiner Siebert; Martina Deckert
Journal:  Acta Neuropathol       Date:  2011-10-22       Impact factor: 17.088

2.  Evidence of canonical somatic hypermutation in hairy cell leukemia.

Authors:  Evgeny Arons; Laura Roth; Jeffrey Sapolsky; Tara Suntum; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Blood       Date:  2011-03-02       Impact factor: 22.113

3.  B cell exchange across the blood-brain barrier in multiple sclerosis.

Authors:  H-Christian von Büdingen; Tracy C Kuo; Marina Sirota; Christopher J van Belle; Leonard Apeltsin; Jacob Glanville; Bruce A Cree; Pierre-Antoine Gourraud; Amy Schwartzburg; Gabriella Huerta; Dilduz Telman; Purnima D Sundar; Tyler Casey; David R Cox; Stephen L Hauser
Journal:  J Clin Invest       Date:  2012-11-19       Impact factor: 14.808

4.  V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity.

Authors:  A R Thompsett; D W Ellison; F K Stevenson; D Zhu
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

5.  Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma.

Authors:  Sarah Moody; Leire Escudero-Ibarz; Ming Wang; Alexandra Clipson; Eguzkine Ochoa Ruiz; Deborah Dunn-Walters; Xuemin Xue; Naiyan Zeng; Alistair Robson; Shih-Sung Chuang; Sergio Cogliatti; Hongxiang Liu; John Goodlad; Margaret Ashton-Key; Markus Raderer; Yingwen Bi; Ming-Qing Du
Journal:  J Pathol       Date:  2017-08-07       Impact factor: 7.996

6.  The I binding specificity of human VH 4-34 (VH 4-21) encoded antibodies is determined by both VH framework region 1 and complementarity determining region 3.

Authors:  Y Li; M B Spellerberg; F K Stevenson; J D Capra; K N Potter
Journal:  J Mol Biol       Date:  1996-03-01       Impact factor: 5.469

7.  Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?

Authors:  Aliki Xochelli; Christina Kalpadakis; Anne Gardiner; Panagiotis Baliakas; Theodoros P Vassilakopoulos; Sarah Mould; Zadie Davis; Evangelia Stalika; George Kanellis; Maria K Angelopoulou; Neil McIver-Brown; Rachel Ibbotson; Sotirios Sachanas; Penelope Korkolopoulou; Anastasia Athanasiadou; Achilles Anagnostopoulos; Helen A Papadaki; Theodora Papadaki; Kostas Stamatopoulos; Gerassimos A Pangalis; David Oscier
Journal:  Blood       Date:  2013-12-03       Impact factor: 22.113

8.  What is immune privilege (not)?

Authors:  Ian Galea; Ingo Bechmann; V Hugh Perry
Journal:  Trends Immunol       Date:  2006-11-28       Impact factor: 16.687

9.  Primary malignant lymphoma of the brain: mutation pattern of rearranged immunoglobulin heavy chain gene.

Authors:  Sumio Endo; Shu-Jing Zhang; Takafumi Saito; Mitsuo Kouno; Toshihiko Kuroiwa; Kazuo Washiyama; Toshiro Kumanishi
Journal:  Jpn J Cancer Res       Date:  2002-12

10.  Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations.

Authors:  R Rosenquist; P Ghia; A Hadzidimitriou; L-A Sutton; A Agathangelidis; P Baliakas; N Darzentas; V Giudicelli; M-P Lefranc; A W Langerak; C Belessi; F Davi; K Stamatopoulos
Journal:  Leukemia       Date:  2017-04-25       Impact factor: 11.528

View more
  5 in total

1.  Characterization of the Intra-tumoral B Cell Immunoglobulin Repertoire Is of Prognostic Value for Esophageal Squamous Cell Carcinoma.

Authors:  Zhizhong Wang; Zhenguo Cheng; Shuangshuang Lu; Louisa S Chard Dunmall; Jun Wang; Yongjun Guo; Yaohe Wang
Journal:  Front Immunol       Date:  2022-06-22       Impact factor: 8.786

2.  Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma.

Authors:  Moritz Bewarder; Maximilian Kiefer; Clara Moelle; Lisa Goerens; Stephan Stilgenbauer; Konstantinos Christofyllakis; Dominic Kaddu-Mulindwa; Natalie Fadle; Evi Regitz; Frank Neumann; Markus Hoth; Klaus-Dieter Preuss; Michael Pfreundschuh; Lorenz Thurner
Journal:  Front Oncol       Date:  2020-11-12       Impact factor: 6.244

Review 3.  Cytologic and Molecular Diagnostics for Vitreoretinal Lymphoma: Current Approaches and Emerging Single-Cell Analyses.

Authors:  Wei Jian Tan; Mona Meng Wang; Paola Ricciardi-Castagnoli; Anita Sook Yee Chan; Tong Seng Lim
Journal:  Front Mol Biosci       Date:  2021-01-11

4.  Novel skewed usage of B-cell receptors in COVID-19 patients with various clinical presentations.

Authors:  Junpeng Ma; Han Bai; Tian Gong; Weikang Mao; Yijun Nie; Xuan Zhang; Yanyan Da; Xiaorui Wang; Hongyu Qin; Qiqi Zeng; Fang Hu; Xin Qi; Bingyin Shi; Chengsheng Zhang
Journal:  Immunol Lett       Date:  2022-08-31       Impact factor: 4.230

5.  Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

Authors:  Andreas Agathangelidis; Anastasia Chatzidimitriou; Katerina Gemenetzi; Veronique Giudicelli; Maria Karypidou; Karla Plevova; Zadie Davis; Xiao-Jie Yan; Sabine Jeromin; Christof Schneider; Lone Bredo Pedersen; Renee C Tschumper; Lesley-Ann Sutton; Panagiotis Baliakas; Lydia Scarfò; Ellen J van Gastel; Marine Armand; Eugen Tausch; Bella Biderman; Constance Baer; Davide Bagnara; Alba Navarro; Anne Langlois de Septenville; Valentina Guido; Gerlinde Mitterbauer-Hohendanner; Aleksandar Dimovski; Christian Brieghel; Sarah Lawless; Manja Meggendorfer; Kamila Brazdilova; Matthias Ritgen; Monica Facco; Cristina Tresoldi; Andrea Visentin; Andrea Patriarca; Mark Catherwood; Lisa Bonello; Andrey Sudarikov; Katrina Vanura; Maria Roumelioti; Hana Skuhrova Francova; Theodoros Moysiadis; Silvio Veronese; Krzysztof Giannopoulos; Larry Mansouri; Teodora Karan-Djurasevic; Raphael Sandaltzopoulos; Csaba Bödör; Franco Fais; Arnon P Kater; Irina Panovska; Davide Rossi; Salem Alshemmari; Panagiotis Panagiotidis; Paul Costeas; Blanca Espinet; Darko Antic; Letizia Foroni; Marco Montillo; Livio Trentin; Niki Stavroyianni; Gianluca Gaidano; Paola Francia di Celle; Carsten Niemann; Elias Campo; Achilles Anagnostopoulos; Christiane Pott; Kirsten Fischer; Michael Hallek; David Oscier; Stephan Stilgenbauer; Claudia Haferlach; Diane Jelinek; Nicholas Chiorazzi; Sarka Pospisilova; Marie-Paule Lefranc; Sofia Kossida; Anton W Langerak; Chrysoula Belessi; Frederic Davi; Richard Rosenquist; Paolo Ghia; Kostas Stamatopoulos
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.